2.50
Hdl Handle:
http://hdl.handle.net/10755/147353
Type:
Presentation
Title:
Intraperitoneal Carboplatin & Taxol for Ovarian Cancer
Abstract:
Intraperitoneal Carboplatin & Taxol for Ovarian Cancer
Conference Sponsor:Sigma Theta Tau International
Conference Year:2005
Author:Ieong, Sao Lan, RN, MS, OCN
P.I. Institution Name:Dekalb Medical Center
Ovarian cancer is the fifth leading cause of tumor death in women. According to the Federation of Gynecology and Obstetrics (FIGO), 80% of all women are diagnosed in advanced stages (III-IV), and the long-term survival for women with advanced stage disease remains low. The main line of treatment for ovarian cancer is cytoreductive surgery and tumor debulking. Interperitoneal chemotherapy (IP chemo) with platinum and taxane is one of the newest treatments for ovarian cancer patients with peritoneal metastasis. Peritoneal space has anatomic advantage as a site for ovarian cancer, because ovarian cancer tends to remain confined within the peritoneal cavity. IP chemotherapy has the advantages of maintaining high concentrations of drugs within peritoneal cavity with less systemic toxicity and improved cell kill than with IV administration of similar doses. Most drugs are 90% absorbed within 4 hours of administration. The peak ascitic fluid levels are 18-24 times higher than peak serum levels for IP carboplatin. Factors affecting IP chemotherapy include drug distribution, penetration, exposure and resistance. Patient eligibility for IP chemotherapy includes those with disease of <1cm confined to the abdominal cavity, patients with ascites but no dense adhesions, and those with prior whole abdominal radiation. Major adverse effects are pain, dyspnea, peritonitis, extravasation, or bowel perforation. During IP chemotherapy administration, the chemotherapy will be diluted in 1000cc of NS, and a total of 2000cc of fluid will be infused into peritoneal cavity through a peritoneal catheter. Patients will be asked to change position at 15-min intervals for 2 hours to ensure adequate intra-abdominal distribution. Pertinent nursing documentation include patients' understanding of treatment, use of sterile techniques, amount of fluid infused, and dose of drug administered. Patient education includes discussion of the rationale and adverse effects for IP chemotherapy, and overview of IP procedure.
Repository Posting Date:
26-Oct-2011
Date of Publication:
17-Oct-2011
Sponsors:
Sigma Theta Tau International

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleIntraperitoneal Carboplatin & Taxol for Ovarian Canceren_GB
dc.identifier.urihttp://hdl.handle.net/10755/147353-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Intraperitoneal Carboplatin &amp; Taxol for Ovarian Cancer</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Sigma Theta Tau International</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2005</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Ieong, Sao Lan, RN, MS, OCN</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">Dekalb Medical Center</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">jennieoo@hotmail.com</td></tr><tr><td colspan="2" class="item-abstract">Ovarian cancer is the fifth leading cause of tumor death in women. According to the Federation of Gynecology and Obstetrics (FIGO), 80% of all women are diagnosed in advanced stages (III-IV), and the long-term survival for women with advanced stage disease remains low. The main line of treatment for ovarian cancer is cytoreductive surgery and tumor debulking. Interperitoneal chemotherapy (IP chemo) with platinum and taxane is one of the newest treatments for ovarian cancer patients with peritoneal metastasis. Peritoneal space has anatomic advantage as a site for ovarian cancer, because ovarian cancer tends to remain confined within the peritoneal cavity. IP chemotherapy has the advantages of maintaining high concentrations of drugs within peritoneal cavity with less systemic toxicity and improved cell kill than with IV administration of similar doses. Most drugs are 90% absorbed within 4 hours of administration. The peak ascitic fluid levels are 18-24 times higher than peak serum levels for IP carboplatin. Factors affecting IP chemotherapy include drug distribution, penetration, exposure and resistance. Patient eligibility for IP chemotherapy includes those with disease of &lt;1cm confined to the abdominal cavity, patients with ascites but no dense adhesions, and those with prior whole abdominal radiation. Major adverse effects are pain, dyspnea, peritonitis, extravasation, or bowel perforation. During IP chemotherapy administration, the chemotherapy will be diluted in 1000cc of NS, and a total of 2000cc of fluid will be infused into peritoneal cavity through a peritoneal catheter. Patients will be asked to change position at 15-min intervals for 2 hours to ensure adequate intra-abdominal distribution. Pertinent nursing documentation include patients' understanding of treatment, use of sterile techniques, amount of fluid infused, and dose of drug administered. Patient education includes discussion of the rationale and adverse effects for IP chemotherapy, and overview of IP procedure.</td></tr></table>en_GB
dc.date.available2011-10-26T09:31:32Z-
dc.date.issued2011-10-17en_GB
dc.date.accessioned2011-10-26T09:31:32Z-
dc.description.sponsorshipSigma Theta Tau Internationalen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.